Nebenwirkungen · Raloxifene Teva
Raloxifene Teva 60 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 5–6
HOS-210847 · Präparat HOS-154595
5 Common: Leg cramps Reproductive system and breast disorders Common: Mild breast symptomsa such as pain, enlargement and tenderness General disorders and administration site conditions Very common: Flu syndrome Common: Peripheral oedema Investigations Very common: Increased blood pressurea a Term(s) included based on postmarketing experience. c. Description of selected adverse reactions Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in raloxifene patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % raloxifene and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for raloxifene and 7.1 % placebo). This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-27T11:30:00Z · SHA-256 bbf6706a7418bb5343336909f5773d58520cc2fd4c0b1b303b9821080fd9b117 · Passage eadd16bca3cf11ed3ba93e53576836bea1263849f38a860ed7e81d81e8de1ef0 · Zeichen 2392–3278 im Abschnitt